LABT — Lakewood-amedex Biotherapeutics Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 0.24 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -49.44% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.03 | ||
| Price to Tang. Book | 0.03 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -167.83% | ||
| Return on Equity | -20.76% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | -73.39 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Lakewood-amedex Biotherapeutics Inc is a pharmaceutical company. The Company is focused on addressing unmet needs in the treatment of serious infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains like MRSA, NDM-1, and many others. The Company is engaged in development of its Bisphosphocin class of antimicrobial agents. The Company is exploring additional local drug delivery applications, including complicated urinary tract infections (CAUTI) and pulmonary infections. The Company has a portfolio of compounds that are being profiled for indications such as infected diabetic foot ulcer, urinary tract infections, and pulmonary infections.
Directors
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- June 5th, 2025
- Public Since
- April 23rd, 2026
- No. of Employees
- 5
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 2,369,688
- Address
- 8031 Cooper Creek Blvd., Unit 103, UNIVERSITY PARK, 34201
- Web
- https://lakewoodamedex.com
- Phone
- +1 9412252515
- Contact
- David Irish
- Auditors
- Marcum LLP
Similar to LABT
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
As of Today at 03:43 UTC, shares in Lakewood-amedex Biotherapeutics are trading at $0.49. This share price information is delayed by 15 minutes.
Shares in Lakewood-amedex Biotherapeutics last closed at $0.49 and the price had moved by over the past 365 days. In terms of relative price strength the Lakewood-amedex Biotherapeutics share price has matched the S&P500 Index by over the past year.
There is no consensus recommendation for this security.
Find out moreLakewood-amedex Biotherapeutics does not currently pay a dividend.
Lakewood-amedex Biotherapeutics does not currently pay a dividend.
Lakewood-amedex Biotherapeutics does not currently pay a dividend.
To buy shares in Lakewood-amedex Biotherapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.49, shares in Lakewood-amedex Biotherapeutics had a market capitalisation of $1.16m.
Here are the trading details for Lakewood-amedex Biotherapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: LABT
Based on an overall assessment of its quality, value and momentum Lakewood-amedex Biotherapeutics is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Lakewood-amedex Biotherapeutics is $12.00. That is 2351.48% above the last closing price of $0.49.
Analysts covering Lakewood-amedex Biotherapeutics currently have a consensus Earnings Per Share (EPS) forecast of $4.96 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lakewood-amedex Biotherapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -99.38%.
As of the last closing price of $0.49, shares in Lakewood-amedex Biotherapeutics were trading -93.52% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Lakewood-amedex Biotherapeutics PE ratio based on its reported earnings over the past 12 months is 0.24. The shares last closed at $0.49.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Lakewood-amedex Biotherapeutics' directors